Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
about
Multiple myeloma in the very elderly patient: challenges and solutionsMany multiple myelomas: making more of the molecular mayhemInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationMolecular pathogenesis of multiple myeloma: basic and clinical updatesCost-effectiveness of bortezomib for multiple myeloma: a systematic reviewTime-dependent endpoints as predictors of overall survival in multiple myelomaIAP antagonists induce anti-tumor immunity in multiple myeloma.Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.European perspective on multiple myeloma treatment strategies: update following recent congressesImpact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Molecular pathogenesis of multiple myeloma and its premalignant precursor.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Challenges in multiple myeloma diagnosis and treatment.Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis.Novel treatment paradigm for elderly patients with multiple myeloma.SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.New Treatment Approaches for Older Adults with Multiple Myeloma.Current therapeutic strategy for multiple myeloma.Current approaches for the treatment of multiple myeloma.Diagnosis and therapy of multiple myeloma.Perspectives in the treatment of multiple myeloma.Association of response endpoints with survival outcomes in multiple myeloma.Incorporating novel agents in the management of elderly myeloma patients.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.International Myeloma Working Group recommendations for global myeloma care.Initial treatment of transplant-ineligible patients in multiple myeloma.Optimal management of elderly patients with myeloma.New approaches to management of multiple myeloma.Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
P2860
Q26752991-BA8A7AEC-A705-448B-8170-85E3D0642D0DQ26852892-81DF38CC-20D3-4ABD-A1C1-4A1982030930Q27002668-1B4F3383-A073-4D46-97EE-C87CFA243360Q27026205-0DCA7A7A-5F47-492A-BDD0-4319ACAF9DB7Q28075297-58BD147C-0E1F-42CF-9177-B7907068AF81Q30538040-B4F90A09-CAAD-4524-B899-9DFEC48D4E21Q33914862-7BC0D748-1B17-4065-A348-BE11127C01E1Q34223730-BA794C85-F7BA-42D0-BF12-EE8FF61B15B2Q34595084-4E13098C-2425-462D-96B4-FC3AAD95C0CDQ34634446-75BAC74F-C1FC-4B25-A231-CBB9CB5CBE59Q35081172-C4173686-CBD4-4E83-BFF4-5AD16E092A05Q35794472-25D20F9A-72E5-44EC-964A-8B68A30F11FBQ35932505-04D238D8-BE6C-4E81-8A2D-79B09EB842B2Q35989943-DBEF48F0-1E16-479B-8080-6A85650F702DQ36115680-B1CAEA24-EE9C-4CFE-AFC6-DED34BBA7132Q36290238-743A5C43-8CE9-4A3D-A558-6EDF6384F4EAQ36595290-8456AFBD-DC52-402C-A6E9-946780D960BAQ36852225-EB91058E-DE15-4552-BF4F-EA281B7327C0Q36886641-8BEC1AD0-2B85-4907-914E-935F3FDD4931Q37037265-D9319275-D06B-4419-A71D-F52869CE974FQ37057028-CD19FFD2-444D-430E-8A48-91E5709CE813Q37536148-63DA0A09-CEE6-426D-B113-54C578486941Q37609489-42215AFF-D7B8-400F-A78C-56573D28FE55Q37970604-C6AC8230-993F-4573-A132-F3E76C863818Q37995195-632DDF12-8580-436C-BBC1-1A4F9D0A760EQ38000078-DF151218-1C51-495C-BD59-036ACE53FAE9Q38048281-63140E7B-5B7C-4AA7-B6F8-D334B657BF13Q38072022-0AC42BBA-7EB0-4A03-8B98-7AC1013FE750Q38087939-53850270-EB9C-4224-AA4C-F22E6B885C1FQ38107482-9089A8BF-9C6B-40F1-80D8-15B565D70208Q38108391-97F04ACE-0FB4-425A-9B5B-5CFDDA7454D1Q38122624-56D142ED-FF58-4EBB-B4C8-C9BB0CEC6316Q38146974-BD0C3BE0-0ECB-4650-8687-54D6A991948BQ38148272-2AD8B7B9-3707-45E4-91F2-6DD165FFF7DAQ38157532-914A4A98-9EF6-4D52-AD68-A96C3AC11AC9Q38168891-E0E3CA12-1FFE-433B-88D1-04335FC5C9FCQ38168925-21F60618-B8E3-4119-A930-CEE66E7E0B2BQ38191867-C4560F40-7AF1-459A-A50E-5DDE8E264B30Q38191975-23B5509C-F771-4897-962D-E95040F8753BQ38192044-9F162E65-78B4-4FA1-B056-1944E70B1DA7
P2860
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cyclophosphamide, thalidomide, ...... or autologous transplantation.
@ast
Cyclophosphamide, thalidomide, ...... or autologous transplantation.
@en
type
label
Cyclophosphamide, thalidomide, ...... or autologous transplantation.
@ast
Cyclophosphamide, thalidomide, ...... or autologous transplantation.
@en
prefLabel
Cyclophosphamide, thalidomide, ...... or autologous transplantation.
@ast
Cyclophosphamide, thalidomide, ...... or autologous transplantation.
@en
P2093
P2860
P1433
P1476
Cyclophosphamide, thalidomide, ...... for autologous transplantation
@en
P2093
Alexander J Szubert
Claudius Rudin
Faith E Davies
Fiona M Ross
Gordon Cook
Graham H Jackson
Huw Roddie
J Anthony Child
Mark T Drayson
NCRI Haematological Oncology Study Group
P2860
P304
P356
10.1182/BLOOD-2011-02-338665
P407
P577
2011-06-07T00:00:00Z